Singaporean authorities do not believe there is sufficient evidence supporting the efficacy of “raw” cannabis, considering the plant and its derivatives to be a dangerous drug with few medical benefits ...
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sectors, with a focus on non-US markets. Most content is available to subscribers only.